<DOC>
	<DOCNO>NCT00780091</DOCNO>
	<brief_summary>OPTIMON compare efficacy cost two monitoring strategy : one base classic standard quality assurance , one priori `` optimize '' main scientific regulatory principle .</brief_summary>
	<brief_title>Optimisation Monitoring Clinical Research Studies</brief_title>
	<detailed_description>There validated standard monitoring strategy clinical research study . Optimon compare two monitoring strategy - classical strategy base practice pharmaceutical industry , optimize strategy base patient 's risk level - ability produce exact data , focus main quality criterion : regulatory requirement scientific validity result . Optimon non inferiority randomize trial .</detailed_description>
	<criteria>Clinical Research Studies : risk level A , B , C Optimon riskassessment scale , without sponsor advice ethical committee , start 2008 end end 2010 , foreseen accrual 20 patient , multicentric least 4 clinical site , paper electronic CRF , participate agreement coordinate investigator sponsor . Clinical site : Sites foresee accrual 5 patient least , participate agreement principal investigator . Clinical Research Units : label institution , least 2 year experience multicentric study , SOPs finalize 2008 , willing participate Optimon .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>optimization</keyword>
	<keyword>risk scale</keyword>
	<keyword>non inferiority</keyword>
	<keyword>cluster randomization</keyword>
	<keyword>monitoring strategy</keyword>
</DOC>